Biogen Pharmachem Industries Ltd
Incorporated in 1995, Biogen Pharmachem Industries Ltd is in the business of trading
in shares and securities.[1]
- Market Cap ₹ 40.0 Cr.
- Current Price ₹ 0.38
- High / Low ₹ 0.93 / 0.34
- Stock P/E 46.5
- Book Value ₹ 0.94
- Dividend Yield 0.00 %
- ROCE 1.01 %
- ROE 0.90 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Stock is trading at 0.41 times its book value
Cons
- Company has a low return on equity of 1.11% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Financial Services Financial Services Finance Other Financial Services
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.11 | 0.95 | 0.00 | 1.62 | 2.47 | 0.00 | 2.38 | 1.20 | 2.56 | |
| 0.04 | 0.03 | 0.12 | 6.72 | 0.95 | 0.12 | 3.22 | 2.49 | 0.45 | 0.45 | 1.49 | 1.60 | |
| Operating Profit | -0.04 | -0.03 | -0.12 | -6.61 | 0.00 | -0.12 | -1.60 | -0.02 | -0.45 | 1.93 | -0.29 | 0.96 |
| OPM % | -6,009.09% | 0.00% | -98.77% | -0.81% | 81.09% | -24.17% | 37.50% | |||||
| 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 | 0.91 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.14 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 0.96 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.42% | |
| -0.13 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 0.86 | |
| EPS in Rs | -0.00 | -0.00 | -0.00 | -0.09 | 0.00 | -0.00 | -0.02 | -0.00 | 0.01 | 0.03 | -0.00 | 0.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | % |
| TTM: | 113% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 41% |
| 5 Years: | 20% |
| 3 Years: | 85% |
| TTM: | 397% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 14% |
| 3 Years: | -13% |
| 1 Year: | -53% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 90.26 |
| Reserves | -4.27 | -4.30 | -4.42 | -10.98 | -10.99 | -9.51 | -11.12 | -11.13 | -10.67 | -8.74 | 26.67 | 8.83 |
| 10.00 | 6.21 | 0.72 | 0.01 | 0.63 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 2.49 | 1.64 | 1.69 | 1.64 | 2.73 | 0.03 | 0.11 | 0.82 | 0.24 | 0.30 | 0.09 | 0.31 | |
| Total Liabilities | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.40 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 43.78 | 26.69 | 22.39 | 3.52 | 6.25 | 6.45 | 9.49 | 6.95 | 8.85 | 5.44 | 23.84 | 32.78 |
| 29.70 | 42.12 | 40.86 | 52.41 | 51.38 | 49.64 | 44.76 | 48.00 | 45.98 | 51.38 | 68.18 | 66.62 | |
| Total Assets | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.40 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.28 | 4.68 | -0.07 | -13.65 | 0.09 | -1.21 | 3.95 | 1.40 | 1.70 | 1.94 | -1.08 | 1.57 | |
| 17.08 | 17.08 | 4.30 | 14.32 | -0.72 | 1.54 | -3.64 | -1.32 | -1.66 | -2.06 | -32.62 | -9.56 | |
| -11.19 | -21.74 | -4.31 | -0.71 | 0.62 | -0.32 | -0.31 | 0.00 | 0.00 | 0.00 | 35.70 | 6.30 | |
| Net Cash Flow | -1.38 | 0.02 | -0.07 | -0.03 | -0.02 | 0.00 | 0.00 | 0.08 | 0.05 | -0.11 | 2.00 | -1.69 |
| Free Cash Flow | -7.28 | 4.68 | -0.07 | -13.65 | 0.09 | -1.21 | 3.95 | 1.40 | 1.70 | 1.94 | -1.08 | 1.57 |
| CFO/OP | 18,200% | -15,600% | 58% | 207% | 1,008% | -247% | -7,000% | -378% | 101% | 372% | 164% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Inventory Days | 0.00 | 0.00 | 0.00 | |||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Working Capital Days | 23,194.09 | 2,651.05 | 549.75 | 152.21 | -35.27 | 170.33 | -19.96 | |||||
| ROCE % | -0.15% | -0.04% | -0.19% | -11.32% | 0.00% | -0.22% | -2.90% | -0.02% | -0.37% | 3.47% | -0.39% | 1.01% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income on Loans INR |
|
||||||||||
| Number of Companies in Investment Portfolio Number |
|||||||||||
| Revenue Generating Activity - Sales INR |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
10h - Interface Financial Services sold 4,03,03,000 Biogen shares on 18.05.2026; holding fell to 4.84%.
-
Announcement under Regulation 30 (LODR)-Allotment
1d - 15,04,33,833 bonus shares allotted on 18 May 2026, raising paid-up capital to Rs. 1,05,30,36,833.
-
Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
14 May - Company reports no unutilized funds from any public, rights, preferential issue or QIP as of 31 March 2026.
- Regulation 33 Read With Regulation 30 Of SEBI (LODR) Regulations, 2015 ("Listing Regulations") 14 May
-
Board Meeting Outcome for Audited Financial Results Of The Company For The Quarter And Year Ended On 31St March, 2026 And Outcome Of The Board Meeting Held On Thursday 14Th May 2026.
14 May - Board approved audited FY26 results; net profit Rs 85.95 lakh, unmodified audit opinion.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
BPIL is engaged in the business of trading in shares and securities in the present and future markets. It trades in commodities, including agro-based and precious metals, and other goods. The company also provides stock broking and consulting services. In addition, it generates trades and sells wind power